Skip to main content

Table 1 Comparison of parathyroid and concomitant thyroid disease in patients with PHPT vs. SHPT

From: Coexistent papillary thyroid carcinoma diagnosed in surgically treated patients for primary versus secondary hyperparathyroidism: same incidence, different characteristics

  PHPT SHPT p-Value
No. cases (%) No. cases (%)
General data Number of patients 140 (64.5) 77 (35.5)  
Mean age 54.6 ± 13   48.8 ± 12   0.001
Sex < 0.001
 Male 15 39
 Female 125 38
 Female:male ratio 8:1 ~ 1:1
 Preoperative PTH level [pg/ml] 357.51 ± 38.11 1020 ± 161.38 < 0.001
Parathyroid disease Parathyroid surgery* < 0.001
 Single gland parathyroidectomy 116 (82.8) 7 (9.1)
  Right superior gland 17 (14.7) 0 (0)
  Right inferior gland 11 (9.5) 1 (14.3)
  Left superior gland 47 (40.5) 1 (14.3)
  Left inferior gland 38 (32.8) 2 (28.6)
  Ectopic 3 (2.5) 0 (0)
  Unspecified 0 (0) 3 (42.8)
 Two glands parathyroidectomy 8 (5.7) 2 (2.6)
 Subtotal parathyroidectomy 10 (7.2) 66 (85.7)
 Multiple parathyroid surgeries 6 (4.3) 2 (2.6)
Parathyroid morphopatology results* < 0.001
 Parathyroid carcinoma 1 (0.7)
 Parathyroid adenoma 92 (65.7) 3 (3.9)
 Adenomatous hyperplasia 47 (33.6) 74 (96.1)
  Nodular 27 (57.4) 59 (79.7)
  Diffuse 7 (14.9) 3 (4.1)
  Both nodular and diffuse 8 (17.1) 9 (12.1)
  Unspecified 5 (10.6) 3 (4.1)
Thyroid disease Thyroid surgery 75 (53.6*) 31 (40.3*) 0.061
 Adenomectomy 4 (5.3**) 5 (16.1**)
 Lobectomy/Lobisthmectomy 21 (28**) 11 (35.5**)
  Right 7 (33.3**) 6 (63.6**)
  Left 14 (66.7**) 4 (36.4**)
 Subtotal thyroidectomy 1 (0.7**)
 Total thyroidectomy 48 (34.3**) 14 (45.6**)
 Multiple thyroid surgeries 1 (0.7**) 2 (2.6**)
Thyroid morphopathology result
Papillary thyroid carcinoma (PTC) 19 (13.6*)
(25.3**)
9 (11.7*)
(29**)
0.692
0.694
Benign lesions
 Thyroid adenoma
9 (12**)
 Adenomatous/colloid goiter 14 (18.7**) 14 (45.2**)
 Adenomatous/colloid goiter with adenomas 40 (53.3**) 10 (32.3**)
 Hashimoto thyroiditis with nodularization 12 (16**) 6 (19.4**)
 Graves Basedow disease 1 (3.2**)
  1. *percentage of PHPT or SHPT cases, respectively; **percentage of concomitant disease cases